A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Public ClinicalTrials.gov record NCT03344458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.
Study identification
- NCT ID
- NCT03344458
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 298 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2017 (Actual)
- Primary completion
- Feb 21, 2023 (Actual)
- Completion
- Feb 21, 2023 (Actual)
- Last update posted
- Jul 7, 2026
2017 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Pharma Investigational Site | Birmingham | Alabama | 35233 | — |
| Ascendis Pharma Investigational Site | Los Angeles | California | 90048 | — |
| Ascendis Pharma Investigational Site | Orange | California | 92868 | — |
| Ascendis Pharma Investigational Site | Sacramento | California | 95821 | — |
| Ascendis Pharma Investigational Site | Centennial | Colorado | 80112 | — |
| Ascendis Pharma Investigational Site | Jacksonville | Florida | 32207 | — |
| Ascendis Pharma Investigational Site | Orlando | Florida | 32806 | — |
| Ascendis Pharma Investigational Site | Tallahassee | Florida | 32308 | — |
| Ascendis Pharma Investigational Site | Saint Paul | Minnesota | 55102 | — |
| Ascendis Pharma Investigational Site | Jackson | Mississippi | 39216 | — |
| Ascendis Pharma Investigational Site | Lebanon | New Hampshire | 03756 | — |
| Ascendis Pharma Investigational Site | Mineola | New York | 11501 | — |
| Ascendis Pharma Investigational Site | New York | New York | 10029 | — |
| Ascendis Pharma Investigational Site | Cleveland | Ohio | 44195 | — |
| Ascendis Pharma Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Ascendis Pharma Investigational Site | Portland | Oregon | 97227 | — |
| Ascendis Pharma Investigational Site | Portland | Oregon | 97239 | — |
| Ascendis Pharma Investigational Site | Dallas | Texas | 75390 | — |
| Ascendis Pharma Investigational Site | Fort Worth | Texas | 76104 | — |
| Ascendis Pharma Investigational Site | Charlottesville | Virginia | 22908 | — |
| Ascendis Pharma Investigational Site | Norfolk | Virginia | 23507 | — |
| Ascendis Pharma Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03344458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03344458 live on ClinicalTrials.gov.